Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
Additional Novel Oral Anticoagulants are Expected to Gain Approval in China for AF and VTE in the Next Three to Four Years, According to Findings from Decision Resources Group
BURLINGTON, Mass., June 10, 2014 /PRNewswire/ -- Decision Resources Group finds that the high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs) in the Chinese market. Warfarin, the mainstay of anticoagulation treatment, is listed in the national essential drugs list and is therefore fully reimbursed by the public health insurance schemes. According to our findings, over 90 percent of surveyed cardiologists are prescribing warfarin therapy for venous thromboembolism (VTE), and over half of them are prescribing warfarin for patients with atrial fibrillation (AF) with a higher risk of stroke, some in combination with aspirin. The emergence of several NOACs in recent years, however, is expected to reduce warfarin's market share in the coming years.
Other key findings from the Emerging Markets Physician & Payer Forum report entitled Novel Oral Anticoagulants in China: Physician and Payer Perspectives on the Evolving Treatment of Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome:
Comments from Decision Resources Group Analyst Jonathan Chan, M.MedSc.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.